Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma. Issue 4 (5th May 2021)

• Record Type: Journal Article
• Authors: Yang, John Jeongseok; Ryu, Kyong‐Suk; Kim, Jin Seok; Chung, Yousun; Kim, Hyungsuk; Hwang, Sang‐Hyun; Oh, Heung‐Bum; Ko, Dae‐Hyun
• Is Part Of: Journal of clinical apheresis. Volume 36:Issue 4(2021)
• Page Start: 628
• Page End: 633
• Publication Date: 2021-05-05
• Subjects: desensitization -- hemolysis -- incompatible -- plasma -- safety -- therapeutic plasma exchange; Hemapheresis -- Periodicals; Blood -- Transfusion -- Periodicals; Blood -- Transfusion, Autologous -- Periodicals; Cell separation -- Periodicals; Leukapheresis -- Periodicals; Plasmapheresis -- Periodicals; 615.39
• DOI: 10.1002/jca.21904
• Languages: English
• ISSNs: 0733-2459

Abstract

Abstract: Background: Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims: This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Materials & Methods: Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described. Results: The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported. Discussion: While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events. Conclusions: Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.